Published in Clin Cancer Res on March 15, 2007
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol (2009) 2.04
Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 1.73
Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.30
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res (2008) 1.24
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother (2010) 0.88
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers. Cancer Immunol Immunother (2013) 0.84
Immunomodulation of breast cancer via tumor antigen specific Th1. Cancer Res Treat (2009) 0.84
Unraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model. J Immunol (2012) 0.80
The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent. Clin Cancer Res (2015) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 2.54
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res (2007) 2.20
Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods (2005) 2.16
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol (2009) 2.04
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology (2009) 2.04
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol (2006) 1.65
TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res (2011) 1.65
GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat (2009) 1.60
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol (2007) 1.60
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res (2007) 1.59
Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res (2008) 1.59
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 1.55
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol (2006) 1.53
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res (2002) 1.51
Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors. Cancer Res (2007) 1.49
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res (2004) 1.49
CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother (2006) 1.47
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res (2008) 1.38
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol (2006) 1.31
TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol (2011) 1.30
A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology (2012) 1.29
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28
Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol (2010) 1.26
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res (2011) 1.25
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res (2008) 1.24
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res (2006) 1.22
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One (2013) 1.22
The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood (2007) 1.21
Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res (2010) 1.21
Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res (2010) 1.20
Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res (2003) 1.19
Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. J Clin Oncol (2004) 1.19
Renal hemodynamic, inflammatory, and apoptotic responses to lipopolysaccharide in HO-1-/- mice. Am J Pathol (2007) 1.16
Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med (2013) 1.16
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) (2012) 1.15
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther (2008) 1.15
Rheumatoid arthritis and cardiovascular disease. Am Heart J (2013) 1.14
Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. Biomaterials (2010) 1.14
Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res (2005) 1.14
Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J Immunol (2007) 1.14
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol (2004) 1.07
Immunity and immune suppression in human ovarian cancer. Immunotherapy (2011) 1.07
Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J Clin Endocrinol Metab (2009) 1.06
Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals. Psychopharmacology (Berl) (2011) 1.05
ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines (2011) 1.04
Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res (2006) 1.04
LPS-induced murine systemic inflammation is driven by parenchymal cell activation and exclusively predicted by early MCP-1 plasma levels. Am J Pathol (2011) 1.04
Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano (2012) 1.03
Conflicts of interest in translational research. J Transl Med (2004) 1.03
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med (2011) 1.02
TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin Cancer Res (2011) 1.00
Translational Research Working Group developmental pathway for immune response modifiers. Clin Cancer Res (2008) 1.00
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother (2010) 0.99
Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells. J Immunol (2010) 0.98
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med (2010) 0.97
Functional folate receptor alpha is elevated in the blood of ovarian cancer patients. PLoS One (2009) 0.96
Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest (2015) 0.95
Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods (2005) 0.95
Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res Treat (2005) 0.95
Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest (2004) 0.95
Expanding assessments of translational research programs: supplementing metrics with value judgments. Eval Health Prof (2013) 0.94